# TLX591

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/tlx591
Canonical HTML page: https://getyourbrief.com/entity/tlx591

## Timeline

- **2026-Q4**: Interim Analysis — Expected interim efficacy data from the larger global patient cohort.
- **2026-Q3**: Part 2 Expansion — Full global enrollment for efficacy endpoints (rPFS and OS) expected to accelerate.
- **2026-03-10**: Primary Objectives Met — Announcement that Part 1 successfully validated safety and dosimetry profiles.
- **2026-03-10**: Primary Objectives Met — Telix announces Part 1 achieved all primary safety and dosimetry goals.
- **2025-Q4**: Part 1 Completion — Enrollment for the safety and dosimetry portion of the study concludes.
- **2025**: Enrollment Milestone — Completion of patient enrollment for the Part 1 SELECT lead-in phase.
- **2024-Q1**: Study Initiation — Launch of the ProstACT Global Phase 3 study for mCRPC.
- **2024-Q1**: Trial Initiation — ProstACT GLOBAL Phase 3 study begins enrollment.

## Recent coverage (2 stories, network-wide)

### Telix Pharmaceuticals Hits Key Milestone in Phase 3 Prostate Cancer Trial
2026-03-10 00:58:12 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 4

Telix Pharmaceuticals has announced that Part 1 of its ProstACT GLOBAL Phase 3 study for TLX591 successfully met its primary objectives. This milestone confirms the safety and dosimetry of the company's lead radiopharmaceutical candidate for metastatic prostate cancer, clearing the way for full trial expansion.
Full story: https://getbiobrief.com/story/prostact-phase-3-primary-objectives-achieved

### Telix’s ProstACT Phase 3 Hits Primary Goals, Advancing Prostate Cancer Therapy
2026-03-10 00:55:17 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 4

Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Full story: https://gethealthbrief.com/story/telix-prostact-phase-3-primary-objectives-achieved

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.